October 23, 2014 10:31 AM ET

Pharmaceuticals

Company Overview of Materia Medica Holdings Ltd.

Company Overview

Materia Medica Holdings Ltd. engages in the research and manufacturing of homeopathic products. It offers Anaferon, a drug for prevention and treatment of influenza and SARS; Anaferon for children for the treatment and prevention of influenza; Arthrofoon, a drug for course treatment of chronic inflammatory diseases of joints; Afala, a drug for treatment of prostatitis and benign prostate hyperplasia; and Impaza, a product for course treatment of erectile dysfunction of different etiology. The company also provides Proproten-100, a drug for the treatment of alcoholism; Tenoten for acute and chronic stresses and neurosis-like conditions; and Tenoten for children for the treatment of attention ...

3rd Samotechniy per

9 building

Moscow,  127473

Russia

Founded in 1992

Phone:

7 495 684 4333

Fax:

7 495 688 9207

Key Executives for Materia Medica Holdings Ltd.

Materia Medica Holdings Ltd. does not have any Key Executives recorded.

Materia Medica Holdings Ltd. Key Developments

Angel Biotechnology Holdings Plc Confirms Key Parameters of the Joint Venture Agreement with Materia Medica Holdings Ltd

Angel Biotechnology Holdings Plc announced following detailed negotiations in Moscow held on 29 and 30 November 2012, the company confirmed that the key parameters of the joint venture agreement with Materia Medica Holdings Ltd. (OOO NPF Materia Medica Holding ("MMH")) have now been agreed and that completion of legalities and signing of the agreement remain on course for completion before the end of the calendar year. The agreement provides for the transfer of all existing contracts currently carried out by Angel for MMH to the JV company in which Angel will have a minority stake. The terms upon which such contracts are to be transferred will likely give rise to an exceptional book loss in the interim accounts of circa £1.7 million, a substantial portion of which is expected to be recovered in future periods, and a further write off of accrued income in respect of the contracts of circa £0.35 million. Because the liability created will be paid for through the transfer of fixed assets, licensing support and the achievement of milestones by the JV company, the transfer of contracts to the JV is expected to be cash neutral for the Group.

Materia Medica Holdings Ltd. Announces Executive Changes

Materia Medica Holdings Ltd. named John Naylor senior vice president of commercial markets, effective November 19, 2012. Naylor replaces Simeon Schindelman, who has taken the position of CEO of Bloom Health. Naylor joined Medica as vice president and general manager of commercial sales in April 2010.

Similar Private Companies By Industry

Company Name Region
OJSC Research and Production Company FiBr-Med Europe
OJSC OTCPharm Europe
Angelico Pharmaceuticals Europe
Segmenta Pharmaceuticals LLC Europe
FF Lekko ZAO Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Materia Medica Holdings Ltd., please visit www.materiamedica.ru. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.